Key clinical point: Compound CAR T therapy against CLL1 and CD33 appears to be effective, with manageable toxicity.
Major finding: Seven of nine relapsing/refractory acute myeloid leukemia patients had no sign of residual disease 4 weeks afterward.
Study details: Open-label investigation in nine subjects
Disclosures: The work was funded by iCell Gene Therapeutics. Several investigators were employees. The researchers did not report any disclosures.
Liu F et al. EHA Congress. Abstract S149.